Reply to comments on two articles dealing with the teratogenicity of cyproterone acetate (CA) and medroxyprogesterone acetate (MPA)
Spielmann
H
H
D000726:Androgen Antagonists / Q000633:toxicity*; D003271:Contraceptive Agents, Female / Q000633:toxicity*; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000633:toxicity; D017373:Cyproterone Acetate; D004622:Embryo, Mammalian / Q000187:drug effects; D005260:Female; D005865:Gestational Age; D006207:Half-Life; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000633:toxicity; D017258:Medroxyprogesterone Acetate; D011247:Pregnancy; D013723:Teratogens
D000726:Androgen Antagonists; D003271:Contraceptive Agents, Female; D013723:Teratogens; D017373:Cyproterone Acetate; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D008525:Medroxyprogesterone